FDA Rejects Approval of Kangfang Biotech's Cancer Drug Ivonescimab
The U.S. Food and Drug Administration (FDA) has rejected the approval of the cancer drug Ivonescimab submitted by Summit Therapeutics, which was originally developed by China's Kangfang Biotech. Summit Therapeutics is headquartered in Miami, and on Monday, Kangfang Biotech's stock, listed in Hong Kong, fell by 24%. In 2022, Kangfang Biotech licensed the drug to Summit, with a total transaction value of up to $5 billion. In September of this year, AstraZeneca invested $2 billion in Summit and acquired an 11% stake. The FDA stated that the drug has not established sufficient evidence of efficacy and has not shown a significant improvement in patient survival rates. Summit's co-CEO Robert Duggan expressed disappointment regarding this decision. The approval of Ivonescimab by the FDA was one of the first applications for treatment regimens targeting multiple cancers. Analysts pointed out that this rejection was not unexpected and should not affect the applications for the company's other drugs. Among the clinical trial data submitted to the FDA, 62% of the participants were Asian, while 38% were Western, and investment bank TD Cowen raised concerns that the patient composition might influence the FDA's decision. Kangfang Biotech is regarded as a leading company in China's biotechnology industry and secured a significant presentation slot at the American Society of Clinical Oncology (ASCO) annual meeting in June of this year.
-- Price
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.
You may also like

Moderna's Cancer Vaccine Shows Promise, Stock Valuation Raises Concerns

NVIDIA Launches Nemotron for Science to Accelerate Scientific Discoveries with Intelligent Agents

Former Employee Sues Ethereum Foundation, Claims Retaliatory Dismissal After Protesting 'Seppuku' Clause

BRT.Fit Founder Calls for Incorporating Exercise Habits into Cancer Prevention

Nixo sues Ethereum Foundation, Vitalik Buterin over 'suicide pledge' claim

U.S. Senate Rejects Long-Term Regulation Legislation for the Cryptocurrency Industry

Proteomic clocks link accelerated aging to higher risk of death and disease

Aging is not linear: cells go through coordinated stages of deterioration

Trump and Islamophobia: The Chorus That No Longer Mobilizes Votes

Jennifer Tilly Earns Up to $10 Million a Year from The Simpsons Without Ever Participating: Her Story
Anthropic IPO Price Prediction: Where Could ANT Open After Pricing?
Anthropic IPO price prediction: See ANT’s $80–$87 base-case opening range, how the final offer price changes it, and what could push shares above $90.

Japan Proposes Establishing an 'Asian Version of the International Energy Agency' to Enhance Southeast Asia's Oil Storage Capacity in Response to Energy Crises

Federal Reserve Warns Korean Investors About Leveraged ETF Risks

Mercado Bitcoin Withdrawal Update: Pix Restart and Crypto Suspension
Mercado Bitcoin set November 17 for Pix deposits and withdrawals in Brazilian reais. Read the withdrawal rules and the background to the crypto suspension.

Reasons Why Cryptocurrency Kiosks Face Increasing Regulation

The Q3 Market in Turmoil: How Much is Circle Worth?

A Decade of a Crypto Neutral Fund Manager: A High-Pressure Way of Life

JPMorgan and DBS Enable On-Chain USD Payments! 24-Hour Cross-Border Transfers, Ant International Becomes First Client

XRP holders demand Ripple burn 31.1 billion tokens by March 2027

Major Indexes Close Lower, Nvidia Earnings Are Imminent | WEEX Daily Market Brief (November 17, 2026)
At the November 16 close, the three major indexes all finished lower. Technology-stock selling continued, with the chip sector leading declines. Bitcoin’s weekend selloff showed signs of stop-loss hunting; it is currently around $64,000. Backpack received regulatory approval. On November 17, watch for October retail sales data and earnings from Nvidia, Home Depot, Disney, and JD.com.

Cardano vs Solana: Which Blockchain is Superior?

Surge in Drone Demand Drives Swiss Defense Group to Accelerate U.S. Market Expansion

25 million stolen in 12 seconds: the MEV brothers acquitted

Citi Updates Preferred List of U.S. Software Stocks: Box, Navan, and Roper Technologies Take the Top Three Spots

JPMorgan and MIT Map More Than 150 Requirements for Institutional Blockchains

J.P. Morgan Chief Global Strategist: Tech Stock Trading Enters a Phase of Volatility and Uncertainty, Investors Should Diversify AI Holdings

One Hundred Million Dollars in Floating Profit Goes to Zero: A Contract Trader's Dilemma

Figment to Support Staking Through BNY’s Digital Asset Custody Platform

Crypto: Tether Gold (XAU₮) Receives Unqualified Audit from KPMG







